Aplastic anemia medical therapy: Difference between revisions
/* Definitive treatment of aplastic anemia {{cite journal| author=Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al.| title=Guidelines for the diagnosis and management of aplastic anaemia. | journal=Br J Haematol | year= ... |
/* Definitive treatment of aplastic anemia {{cite journal| author=Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al.| title=Guidelines for the diagnosis and management of aplastic anaemia. | journal=Br J Haematol | year= ... |
||
| Line 26: | Line 26: | ||
===Definitive Treatment=== | ===Definitive Treatment=== | ||
* Infection or uncontrolled bleeding should be treated first before giving immunosuppressive therapy | * Infection or uncontrolled [[bleeding]] should be treated first before giving [[immunosuppressive] therapy | ||
* Allogeneic bone marrow transplantation (BMT) from a human leucocyte antigen (HLA)-identical sibling donor | * Allogeneic [[bone marrow transplantation]] (BMT) from a [[human leucocyte antigen]] (HLA)-identical sibling donor | ||
* Immunosuppressive therapy with the standard regimen of antithymocyte globulin (ATG) and ciclosporin | * Immunosuppressive therapy with the standard regimen of [[antithymocyte globulin]] (ATG) and [[ciclosporin]] | ||
* Matched unrelated donor bone marrow transplantation (MUD BMT), if indicated | * Matched unrelated donor [[bone marrow transplantation]] (MUD BMT), if indicated | ||
* Maintain safe platelet count and haemoglobin level with transfusions during pregnancy and consider ciclosporin | * Maintain safe platelet count and [[haemoglobin]] level with transfusions during [[pregnancy]] and consider ciclosporin | ||
'''Note''': Use of haemopoietic growth factors (such as recombinant human erythropoietin [rHuEPO] or G-CSF) and prednisolone were considered but not recommended. | '''Note''': Use of haemopoietic growth factors (such as recombinant human [[erythropoietin]] [rHuEPO] or G-CSF) and [[prednisolone]] were considered but not recommended. | ||
}} | }} | ||
Revision as of 14:45, 23 September 2012
|
Aplastic anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Aplastic anemia medical therapy On the Web |
|
American Roentgen Ray Society Images of Aplastic anemia medical therapy |
|
Risk calculators and risk factors for Aplastic anemia medical therapy |
Editor-In-Chief: Aric Hall, M.D., Beth Israel Deaconess Medical Center, Boston, MA [1]
Overview
Medical therapy of aplastic anemia often includes a short course of anti-thymocyte globulin (ATG or anti-lymphocyte globulin) and several months of treatment with cyclosporin to modulate the immune system. Mild chemotherapy with agents such as cyclophosphamide and vincristine may also be effective. Antibodies therapy, such as ATG, targets T-cells, which are believed to attack the bone marrow. Steroids are generally ineffective.
Medical Therapy
Supportive Care in treatment of aplastic anemia [1] (DONOT EDIT)
| “ |
Supportive Care
|
” |
Definitive treatment of aplastic anemia [1] (DONOT EDIT)
{{cquote|
Definitive Treatment
- Infection or uncontrolled bleeding should be treated first before giving [[immunosuppressive] therapy
- Allogeneic bone marrow transplantation (BMT) from a human leucocyte antigen (HLA)-identical sibling donor
- Immunosuppressive therapy with the standard regimen of antithymocyte globulin (ATG) and ciclosporin
- Matched unrelated donor bone marrow transplantation (MUD BMT), if indicated
- Maintain safe platelet count and haemoglobin level with transfusions during pregnancy and consider ciclosporin
Note: Use of haemopoietic growth factors (such as recombinant human erythropoietin [rHuEPO] or G-CSF) and prednisolone were considered but not recommended. }}
References
- ↑ 1.0 1.1 Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC; et al. (2009). "Guidelines for the diagnosis and management of aplastic anaemia". Br J Haematol. 147 (1): 43–70. doi:10.1111/j.1365-2141.2009.07842.x. PMID 19673883.